Some insurers now cover Wegovy specifically for cardiovascular risk reduction in patients with established heart disease and obesity, even when their weight-loss-only formulary excludes it
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
These simple strategies can make a big difference in how you feel
The side effect profile of retatrutide, as observed in early clinical trials, shares many characteristics with other GLP-1-based therapies
One important change is that they state, GLP-1 RA therapy may be continued preoperatively in patients without elevated risk of delayed gastric emptying. The risk factors they state include: escalation phase of dosing, higher dose, weekly dosing (as opposed to daily dosing), gastrointestinal symptoms (nausea, vomiting, abdominal pain, dyspepsia, constipation), and medical conditions that may cause delayed gastric emptying
Monitoring for spread to other body areas helps distinguish local reaction from developing systemic response
